Peter Perger

Learn More
Die Möglichkeiten der medikamentösen Gerinnungshemmung werden zusehens vielfältiger. Leitlinien der Fachgesellschaften sollen die Patientensicherheit erhöhen und zur Vermeidung von blockadeassoziierten Blutungskomplikationen beitragen. Da Leitlinien nicht nur auf pharmakologischen Fakten, sondern auch auf einer sorgfältigen Evaluation vorliegender(More)
Unexpected bleeding in the perioperative period is largely caused by impaired inherited or drug-induced primary haemostasis. Standard tests for plasma coagulation are predominantly employed to gauge the risk of bleeding. In accordance with several reports the subcommittee for perioperative coagulation (AGPG) of the Austrian Society of Anaesthesia,(More)
Venous thromboembolism (VTE) is a common but often overlooked life-threatening complication of critical illness. The aim of this cross-sectional survey was to assess current practice of thromboprophylaxis as well as adherence to international guidelines. After ethics committee approval, all intensive care units in Austrian hospitals treating adult patients(More)
Metabolic myocardial preservation by means of preischemic insulin administration (glucose-potassium-insulin, GPI; acute parenteral alimentation, APA) with the aim of a preischemic myocardial glycogen enrichment was performed in 20 consecutive CABG patients (12 in the APA group, 8 in the control group). Before and after 30 min of an infusion (APA or 0.9%(More)
Der Großteil unerwarteter Blutungen in der perioperativen Phase ist auf Störungen der primären Hämostase – angeboren oder als Folge von Medikamenteneinnahme – zurückzuführen. Dennoch werden in der klinischen Routine die Standardtests der Gerinnung [aktivierte partielle Thromboplastinzeit (aPTT) und Thromboplastinzeit („prothrombin time“, PT)] erhoben, mit(More)
More efficacious anticoagulant and antiplatelet agents have been introduced in vascular medicine and in the prevention of perioperative venous thromboembolisms. Patient management should be guided by familiarity with the pharmacology of coagulation-altering drugs and by consensus statements. The present paper reviews recommendations from the Austrian Task(More)
Even nowadays and at specialized centers, one of the leading causes of death is exsanguination. Trauma-induced coagulopathy (TIC) occuring with massive blood loss primarily results from loss of coagualtion factors and platelets and is aggravated by hemodilution. In addition, hyperfibrinolysis, hypothermia, acidosis and hypocalcaemia also contribute to the(More)
Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism. As dabigatran has a favourable benefit–risk profile, it is being increasingly(More)